openPR Logo
Press release

Osteoporosis Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health

01-30-2024 05:32 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Osteoporosis Pipeline Assessment: FDA, EMA, and PMDA

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Osteoporosis pipeline constitutes 30+ key companies continuously working towards developing 40+ Osteoporosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Osteoporosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteoporosis Market.

The Osteoporosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Osteoporosis Pipeline Report: https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Osteoporosis treatment therapies with a considerable amount of success over the years.
• Osteoporosis companies working in the treatment market are Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others, are developing therapies for the Osteoporosis treatment
• Emerging Osteoporosis therapies in the different phases of clinical trials are- Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, and others are expected to have a significant impact on the Osteoporosis market in the coming years.
• In March 2023, Teva Pharmaceuticals commenced a randomized, double-blind, multinational, multicenter study aimed at comparing the efficacy, safety, and immunogenicity of TVB-009P and Denosumab (Prolia®) in individuals with postmenopausal osteoporosis. The primary objective of this study is to establish the similarity in efficacy and safety profiles between TVB-009 and Prolia (denosumab). This comprehensive, multinational, multicenter, randomized, double-blind investigation seeks to demonstrate comparable efficacy and safety of TVB-009 when compared to Prolia, both administered subcutaneously at doses of 60 mg every 26 weeks. The study will enroll approximately 326 postmenopausal women diagnosed with osteoporosis, randomizing them to receive either TVB-009 or Prolia.

Osteoporosis Overview
Osteoporosis is a medical condition characterized by the weakening of bones, making them fragile and more susceptible to fractures. It occurs when the density and quality of bone are reduced. Bones naturally undergo a process of remodeling, where old bone tissue is replaced by new bone tissue. In osteoporosis, this balance is disrupted, leading to a decrease in bone density and an increased risk of fractures, typically in the hip, spine, and wrist.

Get a Free Sample PDF Report to know more about Osteoporosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Osteoporosis Drugs Under Different Phases of Clinical Development Include:
• Research programme: Lactocore
• RT-102: Rani Therapeutics
• SHR-1222: Jiangsu HengRui Medicine
• EB613: Entera Bio
• VOLT01: Levolta Pharmaceuticals, Inc.
• CT-P41: Celltrion
• TVB-009: Teva Pharmaceuticals

Osteoporosis Route of Administration
Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Osteoporosis Molecule Type
Osteoporosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Osteoporosis Pipeline Therapeutics Assessment
• Osteoporosis Assessment by Product Type
• Osteoporosis By Stage and Product Type
• Osteoporosis Assessment by Route of Administration
• Osteoporosis By Stage and Route of Administration
• Osteoporosis Assessment by Molecule Type
• Osteoporosis by Stage and Molecule Type
DelveInsight's Osteoporosis Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Osteoporosis product details are provided in the report. Download the Osteoporosis pipeline report to learn more about the emerging Osteoporosis therapies at:
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Osteoporosis Therapeutics Market include:
Key companies developing therapies for Osteoporosis are - Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, Actavis PLC, and others.

Osteoporosis Pipeline Analysis:
The Osteoporosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoporosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoporosis Treatment.
• Osteoporosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoporosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoporosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Osteoporosis drugs and therapies-
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Osteoporosis Pipeline Market Drivers
• Rising geriatric population prone to low bone density, growing investments in research and development, increased Focus on development of biosimilars for the treatment of Osteoporosis are some of the important factors that are fueling the Osteoporosis Market.

Osteoporosis Pipeline Market Barriers
• However, side effects and complications associated with osteoporosis drugs, patent expiration of osteoporosis drugs and other factors are creating obstacles in the Osteoporosis Market growth.

Scope of Osteoporosis Pipeline Drug Insight
• Coverage: Global
• Key Osteoporosis Companies: Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others
• Key Osteoporosis Therapies: Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, and others
• Osteoporosis Therapeutic Assessment: Osteoporosis current marketed and Osteoporosis emerging therapies
• Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market barriers

Request for Sample PDF Report for Osteoporosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Osteoporosis Report Introduction
2. Osteoporosis Executive Summary
3. Osteoporosis Overview
4. Osteoporosis- Analytical Perspective In-depth Commercial Assessment
5. Osteoporosis Pipeline Therapeutics
6. Osteoporosis Late Stage Products (Phase II/III)
7. Osteoporosis Mid Stage Products (Phase II)
8. Osteoporosis Early Stage Products (Phase I)
9. Osteoporosis Preclinical Stage Products
10. Osteoporosis Therapeutics Assessment
11. Osteoporosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Osteoporosis Key Companies
14. Osteoporosis Key Products
15. Osteoporosis Unmet Needs
16 . Osteoporosis Market Drivers and Barriers
17. Osteoporosis Future Perspectives and Conclusion
18. Osteoporosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Osteoporosis Market https://www.delveinsight.com/report-store/osteoporosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Osteoporosis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Osteoporosis Epidemiology https://www.delveinsight.com/report-store/osteoporosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Osteoporosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Osteoporosis Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health here

News-ID: 3365207 • Views:

More Releases from DelveInsight Business Research

Diabetic Macular Edema Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Ox
Diabetic Macular Edema Pipeline and Clinical Trials Assessment 2024: FDA Approva …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Macular Edema pipeline constitutes key companies continuously working towards developing Diabetic Macular Edema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Diabetic Macular Edema Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Macular Edema Market.
Dyslipidemia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Merck Group, Pfizer, Sanofi, Dae
Dyslipidemia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory …
DelveInsight's "Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Dyslipidemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dyslipidemia Market Forecast https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Dyslipidemia
Primary Biliary Cholangitis Market 2032: Epidemiology Review, Pipeline Breakthroughs, Regulatory Highlights by DelveInsight | Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, COUR Pharmaceutical
Primary Biliary Cholangitis Market 2032: Epidemiology Review, Pipeline Breakthro …
DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis
Ataxia Telangiectasia Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, Regulatory Updates by DelveInsight | Acasti Pharma Inc., IntraBio Inc
Ataxia Telangiectasia Market Forecast by 2032: Epidemiology Analysis, Emerging T …
DelveInsight's "Ataxia Telangiectasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ataxia Telangiectasia, historical and forecasted epidemiology as well as the Ataxia Telangiectasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Ataxia Telangiectasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ataxia Telangiectasia Market Forecast https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Osteoporosis

Osteoporosis Drugs Market: Demand for Osteoporosis Drugs High Among Geriatric Po …
The global osteoporosis drugs market is analyzed in a report by Transparency Market Research (TMR). The market is expected to grow due to the increasing geriatric population across the globe. The market for osteoporosis drugs is considered semi-consolidated as a handful of players hold a larger share in the market. As per the analysis, Novartis International AG, Eli Lilly and Company, Merck & Co. Inc., Pfizer Inc., and Amgen Inc.
Osteoporosis Drugs Market : Rising prevalence of osteoporosis and aging populati …
The global osteoporosis drugs market is analyzed in a report by Transparency Market Research (TMR). The market is expected to grow due to the increasing geriatric population across the globe. The market for osteoporosis drugs is considered semi-consolidated as a handful of players hold a larger share in the market. As per the analysis, Novartis International AG, Eli Lilly and Company, Merck & Co. Inc., Pfizer Inc., and Amgen Inc.
Bone Densitometry Scan for Osteoporosis & Osteopenia
Global Bone Densitometers Market: Snapshot Of late, the global bone densitometers market has been registering a phenomenal increase in its size and valuation. The significant rise in the pool of patients suffering from arthritis and vitamin D deficiency, supported by the surge in the geriatric population across the world, have influenced this market substantially. The increasing prevalence of osteoporosis in post-menopausal women is also contributing considerably to the growth of
2022 Osteoporosis Drugs Market Analysis & Forecast
Global Osteoporosis Drugs Market Information, by drug class (Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH) and Others), by route of administration (oral, injectable and others) and by gender (male and female) - Forecast to 2022 The Global Osteoporosis Market to reach 14,300 million by 2022, growing with a CAGR of 4.7%. Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone
Datamonitor Healthcare Osteoporosis KOL Interviews
ReportsWorldwide has announced the addition of a new report title Datamonitor Healthcare Osteoporosis KOL Interviews to its growing collection of premium market research reports. For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/datamonitor-healthcare-osteoporosis-kol-interviews February 03, 2017 Datamonitor Healthcare interviewed an endocrinologist based in the US and a rheumatologist based in the UK to gauge their views on current treatment options, late stage clinical candidates, treatment challenges
Global Postmenopausal Osteoporosis Therapeutics Market
The Postmenopausal Osteoporosis Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. Osteoporosis is one of the most common age related